C Linassier
Overview
Explore the profile of C Linassier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carneiro F, Vinceneux A, Larroquette M, Rony M, Carril L, Laguerre B, et al.
Eur J Cancer
. 2024 Jan;
199:113534.
PMID: 38241819
Background: Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a more favorable prognosis. Gastrointestinal metastases (GIMs) are rare,...
2.
Loriot Y, Pagliaro L, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, et al.
Eur J Cancer
. 2017 Nov;
87:140-146.
PMID: 29149760
Background: The GETUG 13 phase III trial tested personalised chemotherapy based on tumour marker decline in patients with poor-prognosis germ-cell tumour (GCT) and demonstrated that a dose-dense regimen improves progression-free...
3.
Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, et al.
Eur J Cancer
. 2016 Jan;
56:77-84.
PMID: 26824706
Background: Malignant peripheral nerve sheath tumors (MPNST) are a rare subtype of soft tissue sarcoma. They can arise in irradiated fields, in patients with type 1 neurofibromatosis (NF1), or sporadically....
4.
Goncalves A, Pierga J, Ferrero J, Mouret-Reynier M, Bachelot T, Delva R, et al.
Ann Oncol
. 2015 May;
26(8):1692-7.
PMID: 25943350
Background: Inflammatory breast cancer (IBC) is a rare and aggressive disease requiring a multimodal treatment. We evaluated the benefit of adding docetaxel-5-fluorouracil (D-5FU) regimen after preoperative dose-intense (DI) epirubicin-cyclophosphamide (EC)...
5.
Elaidi R, Harbaoui A, Beuselinck B, Eymard J, Bamias A, de Guillebon E, et al.
Ann Oncol
. 2014 Dec;
26(2):378-85.
PMID: 25467013
Background: Although sequential targeted therapy is standard in patients with metastatic clear-cell renal cell carcinoma (m-ccRCC), the choice of drugs and optimal administration sequence have yet to be established. The...
6.
Cassier P, Kantor G, Bonvalot S, Lavergne E, Stoeckle E, Le Pechoux C, et al.
Ann Oncol
. 2014 Jun;
25(9):1854-1860.
PMID: 24914041
Background: The role of adjuvant radiotherapy (RT) in the management of atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WD-LPS) remains controversial. Methods: Two hundred eighty-three patients with operable ALT/WD-LPS, no history of previous...
7.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al.
Br J Cancer
. 2013 Mar;
108(4):887-900.
PMID: 23462807
Background: There are no validated markers that predict response in metastatic renal cell cancer (RCC) patients treated with sunitinib. We aim to study the impact of single-nucleotide polymorphisms (SNPs) that...
8.
Brunereau L, Bruyere F, Linassier C, Baulieu J
Diagn Interv Imaging
. 2012 Apr;
93(4):310-8.
PMID: 22464993
The prognosis for testicular cancer is excellent, with a 5-year survival rate greater than 95%. Patients affected can therefore expect to be cured after treatment. Successful treatment requires assessment of...
9.
Porta C, Tortora G, Linassier C, Papazisis K, Awada A, Berthold D, et al.
Med Oncol
. 2011 Jul;
29(3):1896-907.
PMID: 21735145
With six targeted agents approved (sorafenib, sunitinib, temsirolimus, bevacizumab [+interferon], everolimus and pazopanib), many patients with metastatic renal cell carcinoma (mRCC) will receive multiple therapies. However, the optimum sequencing approach...
10.
Munnier E, Cohen-Jonathan S, Linassier C, Douziech-Eyrolles L, Marchais H, Souce M, et al.
Int J Pharm
. 2008 Aug;
363(1-2):170-6.
PMID: 18687392
A new method of reversible association of doxorubicin (DOX) to superparamagnetic iron oxide nanoparticles (SPION) is developed for magnetically targeted chemotherapy. The efficacy of this approach is evaluated in terms...